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Abstract A detailed kinetic analysis of the recombinant soluble
enzyme 3-hydroxy-3-methylglutaryl CoA reductase (HMGR)
from Trypanosoma cruzi has been performed. The enzyme
catalyzes the normal anabolic reaction and the reductant is
NADPH. It also catalyzes the oxidation of mevalonate but at a
lower proportion compared to the anabolic reaction. We report
that the catalytically active species of HMGR in solution is the
tetrameric form. Fluvastatin inhibited competitively the enzyme
while cerivastatin binds by a mechanism which is more accurately
described by a biphasic process characteristic of a class of ‘slow,
tight-binding’ inhibitors. ß 2002 Federation of European Bio-
chemical Societies. Published by Elsevier Science B.V. All
rights reserved.
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1. Introduction
Inhibitors of ergosterol biosynthesis interfere severely with
the growth of protozoan parasites of the Trypanosomatidae
family such as Trypanosoma cruzi, the causative agent of Cha-
gas’ disease, and various Leishmania species [1^3]. Urbina et
al. [4] have shown with in vivo studies using a murine model
of Chagas’ disease that a combined treatment with mevinolin,
an inhibitor of 3-hydroxy-3-methylglutaryl coenzyme A re-
ductase (HMGR), and azole drugs was able to essentially
eliminate circulating parasites and produce complete protec-
tion against death. The combined administration of ergosterol
biosynthesis inhibitors appears to be a promising strategy for
the development of an e¡ective treatment of Chagas’ disease.
HMGR catalyzes the rate-limiting reaction in cholesterol
biosynthesis, the NADPH-dependent 4e3 reduction of 3-hy-
droxy-3-methylglutaryl-CoA (HMG-CoA) to mevalonate.
This enzyme has been extensively studied as an example of
a key biosynthetic enzyme under regulatory control by several
mechanisms [5,6]. Recently, the crystal structure of the cata-
lytic portion of human HMGR in complexes with HMG-
CoA, and CoA, and with HMG, CoA and NADP has
been published [7]. The biosynthetic HMGRs of eukarya
and archaea utilize NADPH to reduce HMG-CoA to meval-
onate for ultimate synthesis of isoprenoids such as cholesterol.
By contrast, the biodegradative HMGR of Pseudomonas me-
valonii [8^10] utilizes NAD in the oxidative acylation of me-
valonate to HMG-CoA, the ¢rst reaction of mevalonate ca-
tabolism in this organism.
The HMGR of eukaryotes consists of an N-terminal mem-
brane anchor domain joined to a C-terminal catalytic domain
by a short linker region. Non-eukaryotic HMGRs [8^11] lack
membrane anchor domains. In T. cruzi and Leishmania major,
HMGR exists as a soluble form [12,13], and therefore trypa-
nosomatids constitute the sole example of a soluble reductase
in a eukaryotic organism.
In order to provide an appropriate source of enzyme for
functional and structural characterization and to analyze the
interaction of trypanosomatid reductase with inhibitors, we
have expressed T. cruzi HMGR in Escherichia coli. Since it
is soluble, we have puri¢ed and characterized it with respect
to molecular mass, kinetic parameters and inhibitor binding.
2. Materials and methods
2.1. Materials
Inhibitors were kindly provided by Novartis (£uvastatin) and Bayer
(cerivastatin). NaCl, dithiothreitol (DTT), dimethyl suberimidate, di-
methyl adipimidate, diethyl pyrocarbonate, hydroxylamine, (R,S)-
HMG-CoA, NADPH, mevalonate, coenzyme A and NADP were
from Sigma. Leupeptin and IPTG were purchased from Boehringer
Mannheim. Molecular mass markers for SDS^PAGE, acrylamide,
bisacrylamide, N,N,NP,NP-tetramethylenediamine and ammonium per-
sulfate were purchased from Bio-Rad.
2.2. Puri¢cation
Two bu¡ers were used in di¡erent steps of the puri¢cation: bu¡er
A (20 mM sodium phosphate, pH 6.75, 10% glycerol, 100 mM su-
crose, 10 mM DTT) and bu¡er B (20 mM sodium phosphate, pH 7.4,
10% glycerol, 100 mM sucrose, 10 mM DTT). The expression system
construction was reported previously [12]. The expression plasmid
pETTCHMGR was used to transform the E. coli expression host
BL21 (DE3).
A frozen pellet from 2 l of E. coli BL21 (DE3)/pETTCHMGR cells
overproducing T. cruzi HMGR was thawed and resuspended in 30 ml
of ice-cold bu¡er A containing 20 Wg/ml leupeptin. Cells were soni-
cated and centrifuged at 10 000Ug for 30 min at 4‡C. The supernatant
was then treated with 30^50% ammonium sulfate. The 30^50% pre-
cipitate was dissolved in 5^10 ml of bu¡er and frozen at 380‡C; this
fraction retains full activity for several weeks.
The ammonium sulfate fraction was loaded onto a hydroxyapatite
(HAP) chromatography column pre-equilibrated with bu¡er A at
1 ml/min. The HAP column was then washed with three volumes of
bu¡er A and elution was performed with a 0^1.8 M NaCl gradient of
300 ml, with the active peak eluting at 0.9 M NaCl. Active fractions
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were pooled and concentrated with 50% ammonium sulfate. The
precipitate was then applied to a blue-Sepharose column, equilibrated
in bu¡er B at 1 ml/min. The column was washed with three volumes
of bu¡er B, and elution was performed with a 0^1.8 M NaCl gradient
of 120 ml, with the active peak eluting at 0.9 M NaCl. The major
active fractions were pooled, concentrated and resuspended in bu¡er
A for storage.
2.3. Assay for HMG-CoA reductase activity
(R,S)-HMG-CoA-dependent oxidation of NADPH (Sigma) was
monitored at 340 nm in a Hewlett-Packard Model 8452 diode array
spectrophotometer. Because of the instability of NADPH at pH 5.5
and elevated temperatures, we used an initial concentration of
NADPH too great to be measured accurately at 340 nm (e340 = 6220
M31 cm31). Disappearance of NADPH was therefore monitored at
366 nm (e360 = 3300 M31 cm31). Standard assay mixtures contained,
in a ¢nal volume of 200 Wl, 270 mM (R,S)-HMG-CoA, 270 mM
NADPH, 75 mM NaCl, 1.0 mM EDTA, 10 mM DTT, and 150
mM NaxPO4, pH 6.8. Reaction mixtures were ¢rst monitored to
detect any (R,S)-HMG-CoA-independent oxidation of NADPH.
Temperature for the measurements was set at 25‡C.
The standard assay for oxidative acylation of mevalonate con-
tained, in a ¢nal volume of 200 Wl : 160 mM (R,S)-mevalonate, 16
mM CoA, 40 mM NADP, 0.1 M Tris^HCl, pH 8.3. Reactions were
¢rst monitored to detect any CoA-independent reduction of NADP.
One unit of HMG-CoA reductase is de¢ned as the amount of
enzyme which catalyzes the oxidation of 1 Wmol of NADPH per
min. Protein was determined by the method of Bradford [14] using
bovine serum albumin as standard.
2.4. Gel ¢ltration
A Superdex 200 HR 30/10 column attached to an Aº KTA system
(Pharmacia) was used. Protein samples were dissolved in eluting bu¡-
er, 50 mM potassium phosphate pH 7.0, 150 mM NaCl. Standard
proteins for molecular mass determination were from Pharmacia.
2.5. Cross-linking of HMGR
Cross-linking with dimethyl suberimidate was done by the method
of Davies and Stark [15,16]. The conditions of the reaction were: 0.2
M triethanolamine HCl at pH 8.5, the bisimidoester HCl at a con-
centration of 5 mg/ml and the protein concentration was varied from
0.2 to 0.5 mg/ml. The reaction was allowed to proceed at room tem-
perature for 3 h, stopped using trichloroacetic acid 25%, and washed
with acetone. SDS^PAGE electrophoresis and Coomassie blue stain-
ing were used to visualize cross-linking.
3. Results and discussion
3.1. T. cruzi HMGR is a tetramer in solution
For production of recombinant protein, the puri¢cation
protocol included three chromatographic steps which are sum-
marized in Table 1. The yield was 7 mg of puri¢ed recombi-
nant protein per 2 l of culture and enzyme purity was judged
homogeneous by SDS^PAGE (Fig. 1).
To investigate the subunit structure of HMGR, we cross-
linked the puri¢ed enzyme with dimethyl suberimidate accord-
ing to the method of Davies and Stark [15,16]. When the
products of the reaction were analyzed, four major Coomassie
blue staining bands were apparent (Fig. 2). The bands pre-
sumably correspond to the monomeric (46 kDa), dimeric (92
kDa), trimeric (138 kDa) and tetrameric (184 kDa) forms.
Similar results were obtained in cross-linking experiments
with dimethyl adipimidate. In addition size exclusion chroma-
tography on a Superdex 200 HR 30/10 column was used to
study the molecular mass of the native protein and subunit
arrangement. HMGR elutes as a single peak with a retention
time that indicates a molecular mass of 184 kDa. Regarding
the native structure of class I enzymes, the catalytically active
soluble form of human HMGR [17] has been reported to be a
tetramer of approximate Mr 200 000 Da [7]. Likewise, HMGR
from radish seedlings is a tetramer of 45 000 Da subunits [18].
The catalytically active form of the class II P. mevalonii
HMGR in solution, based on gel permeation chromato-
graphic experiments, was reported to be a hexamer [19]. In
the present case the data taken together suggest a tetrameric
conformation for the enzyme. Moreover, structure-based se-
quence alignments of human and T. cruzi HMGR (not
shown) indicate that elements important for the formation
of the tetramer in the human enzyme are all present in the
protozoan structure. Sequence elements important for dimer-
ization are also conserved [7].
3.2. Kinetic characterization
Recombinant T. cruzi HMGR was analyzed for its kinetic
properties. The enzyme catalyzes the reaction with NADPH,
but not with NADH as reductant. NADH oxidation was
assessed using two di¡erent cofactor concentrations (350
and 700 WM) and two di¡erent enzyme concentrations (14
nM and 54 nM). No activity was detectable even when high
concentrations of both cofactor and enzyme were used. Initial
velocity studies regarding NADPH oxidation were determined
at 28‡C. HMGR exhibited optimal activity for the conversion
of HMG-CoA to mevalonate in the pH range 5.7^6.3 (data
not shown). pK1 and pK2 values for the enzyme^substrate
complex obtained from Dixon^Webb log plots were 5.21
and 7.4 respectively. Km values for the overall reaction were
13 þ 2 WM for (R,S)-HMG-CoA and 43 þ 3 WM for NADPH;
Vmax was 28 þ 3 U/mg.
Table 1
Summary of a typical puri¢cation of T. cruzi HMGRa
Fraction Activity (Wmol/min) Total protein (mg) Speci¢c activity (U/mg) Enrichment (fold) Yield (%)
Soluble extract 2409 325 7.4 1 100
Ammonium sulfate 30^50% 1650 110 15 2.02 68
Hydroxyapatite 506 22 23 3.1 21
Blue-Sepharose 196 7 28 3.8 8
aThe data are for the puri¢cation from 2 l of culture.
Fig. 1. Puri¢cation of T. cruzi HMGR. An SDS^PAGE gel was
stained with Coomassie brilliant blue. Lane 1, soluble crude extract;
lane 2, 30^50% ammonium sulfate precipitate; lane 3, HAP fraction
(10 Wg); lane 4, blue-Sepharose fraction (10 Wg).
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For the conversion of mevalonate to HMG-CoA, HMGR
exhibited optimal activity in the pH range 8.7^9.6 (data not
shown) and the pK2 for the enzyme^substrate complex was
7.4. At pH 8.3, Km values for mevalonate, CoA and NADP
were 252 þ 50, 74 þ 15 and 220 þ 20 WM respectively and the
Vmax was 0.86 þ 0.04 U/mg.
The study of the kinetic behavior of the enzyme demon-
strates its equivalence in function with previous reported
HMGRs of class I. In addition, the Km values for HMG-
CoA and NADPH parallel those obtained for other charac-
terized biosynthetic HMGRs. The Kms for NADP, mevalo-
nate and CoA were comparable to those obtained for P. me-
valonii HMGR although the Vmax was considerably lower [20].
In agreement with this observation the nucleotide and de-
duced amino acid sequences determined for T. cruzi and L.
major HMGRs are homologous to the reported sequences of
Fig. 2. A: SDS^PAGE gel of cross-linked HMGR. Puri¢ed HMGR was cross-linked with dimethyl suberimidate (5 mg/ml) for 3 h at room
temperature. The cross-linked enzyme was electrophoresed on 8% SDS gels. Uncross-linked HMGR is shown in lane 1. The concentration of
HMGR utilized was 0.2 mg/ml (2) or 0.5 mg/ml (3). The molecular mass (Mr) standards used were: myosin (209 kDa), galactosidase (124
kDa), albumin (85 kDa) and ovalbumin (45 kDa). B: Chromatography of HMGR on a Superdex 200 HR 30/10 column. Ferritin (439 kDa),
catalase (231 kDa), aldolase (154 kDa), bovine serum albumin (69 kDa) and ovalbumin (43 kDa) were used as relative molecular mass stan-
dards. Data are expressed as the ratio Tr3To/To, where Tr is the retention time and To is the void time estimated using blue dextran.
Fig. 3. A: Progress curves for the binding of cerivastatin to HMGR at 200 WM HMG-CoA. The top line is a control curve with no inhibitor.
The remaining curves, from top to bottom, are for inhibitor concentrations of 25, 50, 75, 112.5 and 250 nM, respectively. B: Plot of the recip-
rocal kobs vs. the reciprocal of the cerivastatin concentration. C: Double reciprocal plots of the inhibition of HMGR by £uvastatin at 10, 30
and 60 nM.
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class I enzymes suggesting a common ancestral origin of these
genes although a distinct feature is that they lack the mem-
brane domain characteristic of eukaryotic reductases.
3.3. Inhibition by £uvastatin and cerivastatin
Statins are potent competitive inhibitors of HMGR. All
share an HMG moiety and rigid hydrophobic groups [21].
We assayed the susceptibility of homogeneous T. cruzi
HMGR to inhibition by £uvastatin and cerivastatin. These
compounds are known to inhibit HMGR from mammals
[21,22]. Fluvastatin was shown to be a classic competitive
inhibitor with respect to HMG-CoA (Fig. 3), with a Ki of
27 þ 3 nM, while cerivastatin behaved as a slow-binding in-
hibitor (Fig. 3). The data was analyzed assuming a two-step
mechanism for binding and the equilibrium constant for the
formation of both the initial (Ki) and ¢nal (Ki*) complexes
were calculated. The slow-binding nature of this inhibitor was
observable when the reaction was initiated with enzyme and
the cerivastatin concentration was varied from 0 to 250 nM; a
time-dependent decrease in the rate was seen that varied as a
function of inhibitor concentration. The kinetics were charac-
teristic of enzyme^inhibitor interactions where the initial step
involves rapid formation of a weak complex, followed by a
slow conversion to the tight-binding complex. We obtained a
value for the rate constant of this slow-binding process by
assuming it was analogous to enzyme inactivation by a
‘slow, tight-binding inhibitor’ [23,24]. First, the progress
curves were analyzed by assuming that the rates of inactiva-
tion re£ected a pseudo-¢rst order process; we computer-¢tted
the data to:
NADP  vf t3vf3vi 13e3kobst=kobs 1
where vi and vf are the initial and ¢nal HMGR steady-state
rates, and kobs is the pseudo-¢rst order rate constant [23,24].
The reciprocals of the observed pseudo-¢rst order rate con-
stants were plotted vs. the reciprocal of the cerivastatin con-
centration, employing (Fig. 3):
1=kobs  1=kslowbind  K i=kslowbind cerivastatin 2
where Ki is the equilibrium constant for the initial inhibition
complex, and kslowbind (k3) is the rate constant for the slow-
binding process of inhibition. The kslowbind for the wild-type
enzyme was 8.73 min31, Ki was 14.9 nM and Ki* 0.3 þ 0.04
nM. Slow-binding inhibition for this kind of compounds has
been previously documented [25] and the values obtained were
comparable to results obtained with inhibition of the human
enzyme by potent lovastatin-related inhibitors suggesting a
similar binding mechanism.
Since inhibitors of HMGR, such as lovastatin, increase the
antiproliferative e¡ects of ketoconazole and terbina¢ne
against T. cruzi in both in vitro and in vivo studies [4], future
studies on the inhibition of the enzyme may be of interest for
its development as a drug target in trypanosomatid protozo-
ans.
Acknowledgements: This work was supported by grants from the
UNDP/World Bank/World Health Organization Program for Re-
search and Training in Tropical Diseases (T24/181/30 ID 980139),
the Spanish Programa Nacional de Biotecnolog|¤a (BIO97-0659), the
EC INCO-DC Project Contract CT98-0371 and the Plan Andaluz de
Investigacio¤n (Cod. CVI-199). R.H. and J.P. are fellows of the Span-
ish PFPI of the Ministerio de Educacio¤n y Ciencia and A.M. is a
fellow of the ICI.
References
[1] Florin-Christensen, M., Florin-Christensen, J., Garin, C., Isola,
E., Brenner, R. and Rasmussen, L. (1990) Biochem. Biophys.
Res. Commun. 166, 1441^1445.
[2] Haughan, P.A., Chance, M.L. and Goad, L.J. (1992) Biochem.
Pharmacol. 44, 2199^2206.
[3] Urbina, J.A. (1997) Parasitology 114, S91^S99.
[4] Urbina, J.A., Lazardi, K., Marchan, E., Visbal, G., Aguirre, T.,
Piras, M.M. and Piras, R. (1993) Agents Chemother. 37, 580^
591.
[5] Brown, M.S. and Goldstein, J.L. (1980) J. Lipid Res. 21, 505^
515.
[6] Brown, M.S. and Goldstein, J.L. (1985) Curr. Top. Cell Regul.
26, 3^15.
[7] Istvan, E.S., Palnitkar, M., Buchanan, S.K. and Deisenhofer, J.
(2000) EMBO J. 19, 819^830.
[8] Rodwell, V.W. (1997) Biochemistry 36, 2173^2177.
[9] Lawrence, C.M., Rodwell, V.W. and Stau¡acher, C.V. (1995)
Science 268, 1758^1762.
[10] Tabernero, L., Bochar, D.A., Rodwell, V.W. and Stau¡acher,
C.V. (1999) Proc. Natl. Acad. Sci. USA 96, 7167^7171.
[11] Lam, W.L. and Doolittle, W.F. (1992) J. Biol. Chem. 267, 5829^
5834.
[12] Pen‹a-D|¤az, J., Montalvetti, A., Camacho, A., Gallego, C., Ruiz-
Pe¤rez, L.M. and Gonza¤lez-Pacanowska, D. (1997) Biochem. J.
324, 619^626.
[13] Montalvetti, A., Pen‹a-D|¤az, J., Hurtado, R., Ruiz-Pe¤rez, L.M.
and Gonza¤lez-Pacanowska, D. (2000) Biochem. J. 349, 27^34.
[14] Bradford, M.M. (1976) Anal. Biochem. 72, 248^254.
[15] Davies, G.E. and Stark, G.R. (1970) Proc. Natl. Acad. Sci. USA
66, 651^656.
[16] Lundblad, R. and Noyes, C.M. (1984) Chemical Reagents for
Protein Modi¢cation, Vol. 1, pp. 105^125, CRC Press, Boca
Raton, FL.
[17] Chin, D.J., Luskey, K.L., Faust, J.R., MacDonald, R.J., Brown,
M.S. and Goldstein, J.L. (1982) Proc. Natl. Acad. Sci. USA 79,
7704^7708.
[18] Geelen, M.J.H., Gibson, D.M. and Rodwell, V.W. (1986) FEBS
Lett. 10, 183^186.
[19] Rogers, K.S., Rodwell, V.W. and Geiger, P. (1997) Biochem.
Mol. Med. 61, 114^120.
[20] Tuajuanda, C., Jordan-Starck, T.C. and Rodwell, V.W. (1989)
J. Biol. Chem. 264, 17913^17918.
[21] Endo, A. (1985) J. Med. Chem. 28, 401^405.
[22] Endo, A., Kuroda, M. and Tanzawa, K. (1976) FEBS Lett. 72,
323^326.
[23] Morrison, J.F. and Walsh, C.T. (1988) Adv. Enzymol. Relat.
Areas Mol. Biol. 61, 201^203.
[24] Schloss, J.V. (1988) Acc. Chem. Res. 21, 348^353.
[25] Louis-Flamberg, P., Peisho¡, C.E., Bryan, D.L., Leber, J., El-
liott, J.D., Metcalf, B.W. and Mayer, R.J. (1990) Biochemistry
29, 4115^4120.
FEBS 25622 9-1-02
R. Hurtado-Guerrrero et al./FEBS Letters 510 (2002) 141^144144
